Risk factors for fragility fractures in patients with immunobullous diseases on long-term systemic glucocorticoids
https://doi.org/10.4081/dr.2024.9813
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Dear Editor, Systemic glucocorticoids remain a cornerstone of therapy in immunobullous diseases. Yet little is known about glucocorticoid induced osteoporosis (GIOP) in patients with immunobullous diseases. We performed a retrospective review of medical records at an immunodermatology clinic in a Singaporean tertiary centre. Inclusion criteria consisted of patients with a newly diagnosed immunobullous condition between January 2011 and October 2017, who were on long-term (>= 3 months) systemic glucocorticoids at a minimum daily dose of prednisolone 15mg. [...]
Homik J, Suarez‐Almazor ME, Shea B, Cranney A, Wells GA, Tugwell P. Calcium and vitamin D for corticosteroid‐induced osteoporosis. Cochrane Database of Systematic Reviews. 1998(2). DOI: https://doi.org/10.1002/14651858.CD000952
Allen CS, Yeung JHS, Vandermeer B, Homik J. Bisphosphonates for steroid‐induced osteoporosis. Cochrane Database of Systematic Reviews 2016, Issue 10 DOI: https://doi.org/10.1002/14651858.CD001347.pub2
Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, Tan SS, Tsou IY, Tan SH. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Archives of dermatology. 2012 Mar 1;148(3):307-14. DOI: https://doi.org/10.1001/archdermatol.2011.354
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis & rheumatology. 2017 Aug;69(8):1521-37. DOI: https://doi.org/10.1002/art.40137
Adler RA, El‐Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL. Managing osteoporosis in patients on long‐term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research. 2016 Jan;31(1):16-35. DOI: https://doi.org/10.1002/jbmr.2708
Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta‐analysis. Journal of Bone and Mineral Research. 2013 Aug;28(8):1729-37. DOI: https://doi.org/10.1002/jbmr.1893
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
